This paper reports the results of a pilot study designed to assess the efficacy of intravenous physostigmine and dietary lecithin for treating memory loss in patients with multiple sclerosis (MS). Four patients with definite MS participated in a two-phase (dose-finding and crossover), double-blind clinical trial. In the dose-finding phase, all patients exhibited an improvement in verbal memory (as assessed by the Selective Reminding Test) at the highest of four doses (1.0 mg). In the double-blind, crossover phase, patients were administered placebo or physostigmine (1.0 mg). A significant improvement in verbal memory was observed in three of four patients during the drug condition. None of the patients reported significant medication side effects. This study provides preliminary evidence that cholinergic pharmacotherapy may be useful in treating memory disturbance in MS.
Colquhoun WPEffects of hyoscine and meclozine on vigilance and short-term memory. Br J Industr Med1962 ;19:287-95.
12.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science1982;215:1237-9.
13.
Coyle JT, Price DL, DeLong MR Alzheimer's disease: a disorder of cortical cholinergic innervation . Science1983;219:1184-90.
14.
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol1981;10:122-6.
15.
Dysken M.A review of recent clinical trials in the treatment of Alzheimer's dementia . Psychiatr Ann1987;17: 178-91.
16.
Corkin S., Davis KL, Growden JH, Usdin E., Wurtman RJAlzheimer's disease: a report of progress in research. New York: Raven Press, 1982.
17.
Jorm AFEffects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature. Aust NZ J Psychiatry1986;20:237-40.
18.
Harbaugh RE , Roberts DW, Coombs DW, Saunders RL, Reeder TMPreliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease . Neurosurgery1984;15:514-18.
19.
Bruno G., Mohr E., Gillespie M., Fedio P.Chase TNMuscarinic agonist therapy of Alzheimer's disease: a clinical trial of RS-86 . Arch Neurol1986;43:659-61.
20.
Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983;13:227-31.
21.
Buschke H., Fuld PAEvaluating storage, retention, and retrieval in disordered memory and learning . Neurology1974;24:1019-25.
22.
Levin HS, Benton AL, Grossman RGNeurobehavioral consequences of closed head injury. New York: Oxford University Press, 1982 .
23.
Pavio A., Yuille JC, Madigan SAConcreteness, imagery, and meaningfulness values for 925 nouns. J Exp Psychol Monogr1968;76 (1,Pt. 2):1-25.
24.
Kucera N., Francis WNComputational analysis of present-day American English. Providence, RI: Brown University Press, 1967.
25.
Christian J. , Bickley W., Tarka M., Clayton K.Measures of free recall of 900 English nouns: correlations with imagery, concreteness, meaningfulness, and frequency. Memory Cognition1978;6:379-90.
26.
Mohs RC, Davis BM, Greenwald BS, et al. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies. J Am Geriatr Soc1985;33:749-57.
27.
Thal LJ, Fuld PA, Masur DM, Sharpless NSOral physostigmine and lecithin improve memory in Alzheimer's disease . Ann Neurol1983;13:491-6.
28.
Wettstein A.No effect from double-blind trial of physostigmine and lecithin in Alzheimer's disease. Ann Neurol1983;13:210-12.
29.
Thal LJ, Fuld PAMemory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med1983;308:720.
30.
Beller SA, Overall JE, Swann ACEfficacy of oral physostigmine in primary degenerative dementia: a double-blind study of response to different dose level. Psychopharmacology1985;87:147-51.
31.
Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease . Am J Psychiatry1985;142:28-33.
32.
Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P.Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry1986;10:627-36.
33.
Peters BH, Levin HSChronic oral physostigmine and lecithin administration in memory disorders of aging. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ, eds. Alzheimer's disease: a report of progress in research. New York: Raven Press, 1982:421-426.
34.
Catsman-Berrevoets CE, Van Harskamp F, Appelhof A.Beneficial effect of physostigmine on clinical amnesic behaviour and neuropsychological test results in a patient with a post-encephalitic amnesic syndrome [letter]. J Neurol Neurosurg Psychiatry1986; 49:1088-90.
35.
Goldberg E. , Gerstman LJ, Mattis S., Hughes Jeo, Bilder RM, Sirio CAEffects of cholinergic treatment on post-traumatic anterograde amnesia. Arch Neurol1982;39: 581.
36.
Rogers JD, Brogan D., Mirra SSThe nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol1985;17:163-70.
37.
Squire LRMechanisms of memory. Science1986 ;232: 1612-19.
38.
Ruberg M., Villageois A., Bonnet A., Pillon B., Rieger F., Agid Y.Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems . J Neurol Neurosurg Psychiatry1987;50:538-43.
